IMMvention Therapeutix Partners with Novo Nordisk to Co-develop Oral BACH1 inhibitors for Chronic Conditions

Shots:

• IMMvention & Novo Nordisk have entered into a strategic collaboration & license agreement to jointly develop oral BACH1 inhibitors for SCD & other chronic conditions
• As per the terms, Novo Nordisk will get an exclusive worldwide license of the systemic BACH1 program, while IMMvention retains rights to develop brain-penetrant BACH1 inhibitors, targeting diseases like Parkinson’s & Alzheimer’s
• The companies will jointly advance BACH1 inhibitors from the program to the development candidate nomination, with Novo Nordisk handling further development, regulatory submissions, & marketing globally after or before its nomination

Ref: Globenewswire | Image: IMMvention & Novo Nordisk

Related News:- Novo Nordisk Expands its Partnership with Valo Health to Discover and Develop Novel Therapies for Cardiometabolic Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com